


How to find us



Event location

German National Academy of Sciences Leopoldina
Jägerberg 1
06108 Halle (Saale)
Germany

Registration

Please register to participate by 2nd April 2024 at:
www.leopoldina.org/en/registration-car-t-cell-therapy

The event is registered as an advanced training event
with the Saxony-Anhalt Medical Association.

The Leopoldina originated in 1652 as a classical scholarly society and now has 1,600 members from almost all branches of science. In 2008, the Leopoldina was appointed as the German National Academy of Sciences and, in this capacity, was invested with two major objectives: representing the German scientific community internationally, and providing policymakers and the public with science-based advice.

The Leopoldina champions the freedom and appreciation of science. It promotes a scientifically enlightened society and the responsible application of scientific insight for the benefit of humankind and the natural world. In its interdisciplinary discourse, the Academy transcends thematic, political and cultural boundaries. It is also an advocate of human rights.



Leopoldina
Nationale Akademie
der Wissenschaften

Expanding the Scope of CAR T Cell Therapy


An Interdisciplinary Discussion

Contact

Stefanie Bohley
German National Academy of Sciences Leopoldina
Department Science–Policy–Society
E-Mail: stefanie.bohley@leopoldina.org

08 – 09 April 2024

German National Academy of Sciences Leopoldina
Jägerberg 1
06108 Halle (Saale), Germany



Expanding the Scope of CAR T Cell Therapy

An Interdisciplinary Discussion

The onset of Chimeric Antigen Receptor (CAR) T cell therapy marks a revolutionary development in the field of immunotherapy, achieving notable success since its approval in 2017 for treating B cell malignancies. Designing a patient's own T cells to specifically identify and eradicate tumor cells has successfully treated individuals with previously incurable hematologic cancers. While CAR T cells are currently predominantly utilized in anti-tumor therapy, their initial conceptualization aimed at a broader objective of targeting membrane antigens, opening the door to numerous potential applications. Subsequent studies have explored the application of CAR T cells in non-malignant pathologies, encompassing autoimmune diseases, infectious diseases, and more recently, conditions such as cardiac fibrosis and cellular senescence. Within this interdisciplinary discussion, we present key findings and implications of CAR-based therapies for non-malignant conditions.

Day 1 – 08 April 2024

01:30 – 01:40 pm

Welcome / Introduction

Thomas Krieg ML, Vice-President of Leopoldina
Andreas Mackensen, Georg Schett ML, *Scientific coordinators*

01:40 – 02:10 pm | Key Note

Status of CAR T cell technology in hematology/oncology

Fabian Müller, *Erlangen*

02:10 – 02:40 pm | Impulse #1 + Discussion

CAR T cells in autoimmune diseases

Georg Schett ML, Andreas Mackensen, *Erlangen*

02:40 – 04:10 pm | Impulse #2 + Discussion

CAAR T cells for autoantibody-mediated diseases

Aimee S. Payne, *New York*

CAR T cells and systemic lupus erythematosus (SLE)

Marko Radic, *Memphis*

CAR T cells and Myasthenia gravis

Dimitrios Mouggiakakos, *Magdeburg*

04:10 – 04:40 pm | Coffee break

04:40 – 05:10 pm | Impulse #3 + Discussion

CAR T cells and cardiac fibrosis

Joel G. Rurik, *Stockholm*

05:10 – 05:40 pm | Impulse #4 + Discussion

CAR T cells and cellular senescence

Scott W. Lowe, *New York*

05:45 – 06:45 pm

Plenary discussion

Georg Schett ML, Elmar Jaeckel, Marion Subklewe,
Georg Stingl ML, Janina Paech (Patient)

Day 2 – 9 April 2024

09:00 – 09:10 am

Recap and prospect

Andreas Mackensen, *Erlangen*

09:10 – 09:40 am | Impulse #5 + Discussion

CAR T cells targeting HIV

Steven Deeks, *San Francisco*

09:40 – 10:10 am | Impulse #6 + Discussion

CAR T cells and hepatitis B

Ulrike Protzer, *Munich*

10:10 – 10:40 am | Coffee break

10:40 – 11:10 am | Impulse #7 + Discussion

CAR Treg cells in organ transplantation and autoimmune disease

Elmar Jaeckel, *Toronto*

11:10 – 12:10 am | Impulse #8 + Discussion

Investigator initiated trials with CAR T cells:

Regulation and Point of Care production

Michael Schmitt, *Heidelberg*

Investigator initiated trials with CAR T cells:

Future development

Marion Subklewe, *Munich*

12:10 am – 12:30 pm

Final discussion

12:30 pm | Refreshment and farewell